|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Avista Capital Partners, a private equity firm. |
|---|---|
| Transferring Party | Bristol-Myers Squibb Company (NYSE: BMY), a global manufacturer of pharmaceuticals and other healthcare-related products. |
| Sector | Diagnostics |
| Date | December 17, 2007 |
| Analysis Divestiture is part of BMY's plan to focus on Biopharma. Avista acquires a key supplier of medical imaging products for nuclear and ultrasound cardiovascular diagnostic imaging procedures. Adds to Avista's growing healthcare portfolio. Deal value -- $525m. Defying the rocky structured debt climate, a few days before, Avista agreed to buy Boston Scientific's fluid management and venous access businesses for $425m. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |